Home › Compare › PMXSF vs STAG

PMXSF vs STAG: Dividend Comparison 2026

PMXSF yields 7692.31% · STAG yields 3.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PMXSF wins by $4177739098279589.00M in total portfolio value
10 years
PMXSF
PMXSF
● Live price
7692.31%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4177739098279589.00M
Annual income
$4,073,565,928,588,968,500,000.00
Full PMXSF calculator →
STAG
STAG Industrial Inc.
● Live price
3.44%
Share price
$36.06
Annual div
$1.24
5Y div CAGR
0.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18.3K
Annual income
$462.70
Full STAG calculator →

Portfolio growth — PMXSF vs STAG

📍 PMXSF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPMXSFSTAG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PMXSF + STAG cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
PMXSF pays
STAG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PMXSF
Annual income on $10K today (after 15% tax)
$653,846.15/yr
After 10yr DRIP, annual income (after tax)
$3,462,531,039,300,623,000,000.00/yr
STAG
Annual income on $10K today (after 15% tax)
$292.69/yr
After 10yr DRIP, annual income (after tax)
$393.29/yr
At 15% tax rate, PMXSF beats the other by $3,462,531,039,300,623,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PMXSF + STAG for your $10,000?

PMXSF: 50%STAG: 50%
100% STAG50/50100% PMXSF
Portfolio after 10yr
$2088869549139794.50M
Annual income
$2,036,782,964,294,484,200,000.00/yr
Blended yield
97.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on STAG right now

PMXSF
No analyst data
Altman Z
-40.9
Piotroski
2/9
STAG
Analyst Ratings
9
Buy
9
Hold
3
Sell
Consensus: Buy
Price Target
$45.00
+24.8% upside vs current
Range: $39.00 — $59.00
Altman Z
1.2
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PMXSF buys
0
STAG buys
0
No recent congressional trades found for PMXSF or STAG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPMXSFSTAG
Forward yield7692.31% ✓3.44%
Annual dividend / share$2.00 ✓$1.24
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0.3% ✓
Portfolio after 10y$4177739098279589.00M ✓$18.3K
Annual income after 10y$4,073,565,928,588,968,500,000.00 ✓$462.70
Total dividends collected$4170772265337663.00M ✓$4.0K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: PMXSF vs STAG ($10,000, DRIP)

YearPMXSF PortfolioPMXSF Income/yrSTAG PortfolioSTAG Income/yrGap
1← crossover$779,931$769,230.77$10,665$345.38+$769.3K → PMXSF
2$56,904,315$56,069,789.30$11,365$358.01+$56.89M → PMXSF
3$3,884,151,673$3,823,264,055.84$12,099$370.76+$3884.14M → PMXSF
4$248,050,254,929$243,894,212,638.74$12,870$383.63+$248050.24M → PMXSF
5$14,822,056,221,428$14,556,642,448,653.80$13,678$396.60+$14822056.21M → PMXSF
6$828,776,618,419,079$812,917,018,262,150.50$14,526$409.67+$828776618.40M → PMXSF
7$43,367,472,132,823,630$42,480,681,151,115,220.00$15,413$422.82+$43367472132.81M → PMXSF
8$2,123,871,047,251,591,000$2,077,467,852,069,469,400.00$16,343$436.05+$2123871047251.57M → PMXSF
9$97,358,102,514,598,310,000$95,085,560,494,039,100,000.00$17,315$449.35+$97358102514598.30M → PMXSF
10$4,177,739,098,279,589,000,000$4,073,565,928,588,968,500,000.00$18,332$462.70+$4177739098279589.00M → PMXSF

PMXSF vs STAG: Complete Analysis 2026

PMXSF — Stock

Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol Respiratory Business and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of oral pan-lysyl oxidase inhibitors (LOX) targeting myelofibrosis and other cancers; topical pan-LOX inhibitors targeting skin scarring after events, such as accidents, surgery,and burns; selective Lysyl Oxidase Like Inhibitors (LOXL2) targeting chronic fibrotic diseases, including kidney fibrosis, pulmonary fibrosis, liver fibrosis, and cardiac fibrosis; and semicarbazide-sensitive amine oxidase for neuro inflammatory diseases. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.

Full PMXSF Calculator →

STAG — REIT

STAG Industrial, Inc. (NYSE: STAG) is a real estate investment trust focused on the acquisition and operation of single-tenant, industrial properties throughout the United States. By targeting this type of property, STAG has developed an investment strategy that helps investors find a powerful balance of income plus growth.

Full STAG Calculator →
📬

Get this PMXSF vs STAG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PMXSF vs SCHDPMXSF vs JEPIPMXSF vs OPMXSF vs KOPMXSF vs MAINPMXSF vs PLDPMXSF vs EQRPMXSF vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.